D-0361-2022 Class II Terminated

Recalled by SUN PHARMACEUTICAL INDUSTRIES INC — Princeton, NJ

FDA drug recall D-0361-2022 was initiated by SUN PHARMACEUTICAL INDUSTRIES INC on Oct 22, 2021 and is designated Class II. Reason for recall: Failed Tablet/Capsule Specifications: Out of Specification results for particle Size Distribution and Bulk Density of the Active Pharmaceutical Ingredient. The recall status is terminated (terminated Apr 6, 2023). Affected quantity: 696 Bottles.

Recall details

Product Type
Drugs
Report Date
Jan 12, 2022
Initiation Date
Oct 22, 2021
Termination Date
Apr 6, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
696 Bottles

Product description

Pregabalin Capsules, 50 mg, 100 count bottle, Rx only, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512, Manufactured by: Sun Pharmaceutical Industries Ltd., Survey No. 259/15 Dadra-396 191, (U.T. of D & NH), India, NDC 47335-687-88.

Reason for recall

Failed Tablet/Capsule Specifications: Out of Specification results for particle Size Distribution and Bulk Density of the Active Pharmaceutical Ingredient.

Distribution pattern

Nationwide in the USA

Code information

Lot number: DNC0432A, expiration 01/2023

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0361-2022
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0361-2022. Report a data issue: hello@regdatalab.com.